Your browser is no longer supported. Please, upgrade your browser.
Settings
SVA [NASD]
Sinovac Biotech Ltd.
Index- P/E38.51 EPS (ttm)0.17 Insider Own43.46% Shs Outstand98.90M Perf Week-2.71%
Market Cap639.90M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float44.27M Perf Month-0.46%
Income- PEG3.21 EPS next Q- Inst Own33.94% Short Float0.42% Perf Quarter-12.33%
Sales264.28M P/S2.42 EPS this Y- Inst Trans- Short Ratio12.22 Perf Half Y0.62%
Book/sh3.10 P/B2.09 EPS next Y- ROA- Target Price6.00 Perf Year-20.07%
Cash/sh- P/C- EPS next 5Y12.00% ROE- 52W Range5.73 - 8.75 Perf YTD-6.77%
Dividend- P/FCF- EPS past 5Y-24.20% ROI- 52W High-26.06% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low12.91% ATR0.18
Employees910 Current Ratio- Sales Q/Q79.40% Oper. Margin- RSI (14)46.31 Volatility2.69% 2.41%
OptionableNo Debt/Eq- EPS Q/Q43.20% Profit Margin- Rel Volume- Prev Close6.47
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume15.38K Price6.47
Recom3.00 SMA20-0.45% SMA50-2.56% SMA200-10.61% Volume0 Change0.00%
Feb-24-21 10:54AM  
Feb-23-21 04:31AM  
Feb-22-21 04:05PM  
09:04AM  
Feb-19-21 09:25AM  
Feb-18-21 05:43PM  
Feb-17-21 06:43PM  
Feb-10-21 12:55PM  
Feb-09-21 04:30AM  
Feb-08-21 07:30AM  
Feb-07-21 05:13PM  
Feb-06-21 04:03AM  
Feb-05-21 06:38PM  
04:05PM  
Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella, pneumococcal polysaccharide, and Sabin inactivated polio vaccines. Further, it is developing rubella vaccine; Sabin-strain inactivated polio vaccine; Sars-coVv-2 (COVID-19) vaccine; and quadrivalent influenza vaccine. Sinovac Biotech Ltd. has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; Dynavax Technologies Corporation to develop a vaccine to prevent COVID-19; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. The company was founded in 1999 and is based in Beijing, the People's Republic of China.